Isolated endarteritis of kidney transplants is increasingly recognized. Notably, microarray studies revealed absence of immunologic signatures of rejection in most isolated endarteritis biopsy samples. We investigated if isolated endarteritis responds to rejection treatment and affects kidney transplant survival. We retrospectively enrolled recipients of kidney transplant who underwent biopsies between 1999 and 2011 at seven American and Canadian centers. Exclusion criteria were recipients were blood group-incompatible or crossmatch-positive or had C4d-positive biopsy samples. After biopsy confirmation, patients were divided into three groups: isolated endarteritis (n=103), positive controls (type I acute T cell-mediated rejection with endarteritis; n=101), and negative controls (no diagnostic rejection; n=103). Primary end points were improved kidney function after rejection treatment and transplant failure. Mean decrease in serum creatinine from biopsy to 1 month after rejection treatment was 132.6 mmol/L (95% confidence interval [95% CI], 78.7 to 186.5) in patients with isolated endarteritis, 96.4 mmol/L (95% CI, 48.6 to 143.2) in positive controls (P=0.32), and 18.6 mmol/L (95% CI, 1.8 to 35.4) in untreated negative controls (P,0.001). Functional improvement after rejection treatment occurred in 80% of patients with isolated endarteritis and 81% of positive controls (P=0.72). Over the median 3.2-year followup period, kidney transplant survival rates were 79% in patients with isolated endarteritis, 79% in positive controls, and 91% in negative controls (P=0.01). In multivariate analysis, isolated endarteritis was associated with an adjusted 3.51-fold (95% CI, 1.16 to 10.67; P=0.03) risk for transplant failure. These data indicate that isolated endarteritis is an independent risk factor for kidney transplant failure.
Etiopathologic studies reveal alloimmune responses as the major cause of late kidney transplant failure. [4] [5] [6] [7] Isolated endarteritis of kidney transplants is a newly reported and increasingly recognized entity. 8 Cohort studies identified patients whose transplanted kidneys stopped working effectively in association with isolated endarteritis. [9] [10] [11] [12] [13] [14] Since its first report in 2007, many patients with isolated endarteritis and a paucity of tubulointerstitial inflammation have been described. [8] [9] [10] [11] [12] [13] [14] Intriguingly, three large genomic studies performed in independent cohorts of .700 recipients of kidney transplants reported minimal transcriptional activity of T lymphocytes, cytokines, and chemokines in kidney transplant biopsies that had isolated endarteritis, detected by microscopic examination, and proposed that isolated endarteritis does not represent true acute T cell-mediated transplant rejection. [9] [10] [11] There is no evidence-based knowledge on morbidity, treatment, and prognosis of isolated endarteritis. The international Banff classification defines types of acute T cell-mediated rejection as types I (tubulointerstitial rejectionwith at least moderate grades of both tubulitis and interstitial inflammation), II (vascular rejection with intimal endarteritis), and III (transmural endarteritis/necrosis). 15 Because of the lack of evidence on clinical outcomes, Banff schema does not specifically address how to interpret isolated endarteritis.
As the Banff Working Group, we performed a multicenter collaborative study to investigate if isolated endarteritis responds to anti-T cell-mediated rejection treatment and affects kidney transplant survival.
RESULTS

Patients
Seven transplant centers in the United States and Canada retrospectively enrolled 307 recipients of kidney transplants biopsied between 1999 and 2011. The patients were divided into three diagnostic groups after confirmation by expert pathology committee biopsy review: 103 patients with isolated endarteritis, 101 positive control patients with type I acute T cell-mediated rejection with endarteritis (type I plus type II or III: tubulointerstitial rejection and endarteritis), and 103 negative control patients with no diagnostic rejection. Key exclusion criteria for all groups were diffuse or focal peritubular capillary complement C4d deposition detected by immunofluorescence or immunohistochemistry, blood group ABO incompatibility, or crossmatch positivity between donor and recipient. Eligibility criteria differed between the study groups. In group 1, patients were eligible if they had isolated endarteritis defined by Banff lesion scores 16 in biopsies and an arteritis score of at least 1 with a tubulitis score of 0 or 1 and an interstitial inflammation score of 0 or 1. In group 2 (positive controls), patients were eligible if they had type I acute T cell-mediated rejection with endarteritis with an arteritis score of at least 1 and both tubulitis and interstitial inflammation scores of 2 or 3. In group 3 (negative controls), patients were eligible if they had no diagnostic rejection defined as an arteritis score of 0 and both tubulitis and interstitial inflammation scores of 0 or 1. Only one biopsy per patient was included (if there were multiple biopsies, the earliest biopsy fulfilling eligibility criteria was selected).
The median incidence of isolated endarteritis (C4d negative) per transplant center was 1.3% in all allograft biopsies from recipients who were blood group-compatible and crossmatch-negative (mean=1.2, SEM=0.3, minimum=0.2, maximum=2.1). Table 1 shows the characteristics of patients at the time of transplantation and biopsies. All groups were donor crossmatch-negative and donor blood group-compatible on similar maintenance immunosuppression regimens, and none had positive C4d staining in biopsies. Interestingly, T cell depletion induction therapy at transplantation was more frequent in patients with isolated endarteritis than positive controls but similar to negative controls (19.4% versus 3.0% versus 13.6%, respectively). The median time from transplantation to biopsy was 42 days in isolated endarteritis, 59 days in positive controls, and 37 days in negative controls (P.0.05). Biopsies performed within the first 1 year after transplantation and after 1 year were 76% and 24% in isolated endarteritis, 76% and 24% in positive controls, and 79% and 21% in negative controls, respectively (P=0.87). Isolated endarteritis was often associated with increased serum creatinine, similar to positive and negative controls. However, protocol biopsies were more frequent in isolated endarteritis than in positive controls but not in negative controls (12.6% versus 3.0% versus 21.4%, respectively). Delayed graft function was also more frequent in isolated endarteritis than in positive controls but not in negative controls (14.6% versus 3.0% versus 7.8%, respectively).
Of 307 patients, 117 patients had available donor-specific HLA antibody (DSA) data in the peribiopsy period (median=4 days, range=0-90 days). The frequency of positive DSA was similar among groups: 18.3% of patients with isolated endarteritis, 20.8% of positive controls, and 18.2% of negative controls (P=0.95).
Morphologic Signatures in Biopsies
Isolated endarteritis ( Figure 1A ) is defined as localized arteritis in the absence of diagnostic tubulointerstitial rejection (Banff type I acute T cell-mediated rejection). 8 Positive controls included biopsies with type I acute T cell-mediated rejection with endarteritis, and negative controls included biopsies without diagnostic rejection showing normal histology (n=30), acute tubular injury (n=30), or borderline (n=34) or trivial (n=9) inflammation below the diagnostic cutoff for rejection according to international criteria. 15, 16 We compared the grades of morphologic abnormalities in different microcompartments of biopsies ( Figure 1B) . Patients with isolated endarteritis compared with negative controls had more arteritis, tubulointerstitial inflammation, microvascular inflammation (sum of glomerulitis and capillaritis scores), transplant glomerulopathy, and arteriosclerosis but negligible kidney fibrosis. Patients with isolated endarteritis compared with positive controls had a similar degree of arteritis, less tubulointerstitial inflammation and capillaritis, and more transplant glomerulopathy, arteriosclerosis, and glomerulitis. The grade of arteritis was v1, v2, or rarely, v3 in 92%, 7%, and 1% in patients with isolated endarteritis compared with 93%, 5%, and 2% in positive controls, respectively (P=0.72). The frequency of transplant glomerulopathy was slightly higher in patients with isolated endarteritis (17%) than positive (10%) or negative (6%) controls (P=0.05). The findings that 17% of patients with isolated endarteritis had transplant glomerulopathy in the same biopsy and that 18.3% of patients with isolated endarteritis had concurrent DSA suggest that some isolated endarteritis cases were associated with antibody-mediated injury.
Primary End Points
Response after Rejection Treatment The number of patients who received bolus corticosteroids and T cell depletion did not differ between isolated endarteritis and positive control groups. However, more patients received intravenous Ig or plasmapheresis in the isolated endarteritis group than in positive controls (9.7% versus 1.0%, respectively). Overall, the isolated endarteritis group received rejection treatment less frequently than positive controls (84.5% versus 97.0%, respectively) ( Table 1) . Kidney functional response after rejection treatment was defined by an improvement in renal function by a positive D creatinine value (difference between the serum creatinine value at biopsy and the serum creatinine value at 1 or 6 months after biopsy). Functional response rate after rejection treatment was 80% in patients with isolated endarteritis and 81% in positive controls (P=0.72). Some patients with borderline inflammation or acute tubular injury had received empirical rejection treatment; therefore, kidney functional response after treatment of isolated endarteritis or in positive controls was compared with 30 untreated patients whose biopsies showed normal histology. Rejection treatment was associated with a significant decline in serum creatinine at 1 and 6 months in both isolated endarteritis and positive control groups compared with the untreated negative control group with normal histology ( Figure 2 ). Mean decline in serum creatinine at 1 month was 132.6 mmol/L (95% confidence interval [95% CI], 78.7 to 186.5) in patients with isolated endarteritis and 96.4 mmol/L (95% CI, 48.6 to 143.2) in positive controls compared with 18.6 mmol/L (95% CI, 1.8 to 35.4) in patients who were not treated. This functional improvement was maintained at 6 months (mean decline in serum creatinine, 131.7 mmol/L; 95% CI, 80.4 to 183.9 in patients with isolated endarteritis and mean decline in serum creatinine, 115.8 mmol/L and 95% CI, 75.1 to 157.4 in positive controls compared with mean decline in serum creatinine, 30.9 mmol/L; 95% CI, 0.9 to 61.9 in untreated controls).
Prognostic Significance of Isolated Endarteritis
The median follow-up after biopsy was 3.2 years (range=0-13 years) and similar among the three groups (P=0.32). Figure  3 , A and B shows the Kaplan-Meier estimates of 3-and 8-year kidney transplant survival according to the study groups. At 1 year, kidney transplant survival was 90% in patients with isolated endarteritis, 91% in positive controls, and 97% in negative controls (P=0.06). At 3 and 8 years, kidney transplant survival was 85% and 81% in patients with isolated endarteritis, 87% and 79% in positive controls, and 96% and 92% in negative controls, respectively (P=0.01 and P=0.02, respectively). Over the entire follow-up period (median=3.2 years), kidney transplant survival was 79% in patients with isolated endarteritis, 79% in positive controls, and 91% in negative controls (P=0.01).
In univariate analysis, risk for kidney transplant failure was 3.96-fold higher in patients with isolated endarteritis and 3.39-fold higher in positive controls compared with negative controls (Table 2) .
In bivariate risk adjustments, there was a negative association between kidney transplant survival and isolated endarteritis and positive controls compared with negative controls when separately adjusted for several recipient and donor variables, delayed graft function, and biopsy findings ( Figure  3C ). In contrast, the poor prognostic value of isolated endarteritis and type I acute T cell-mediated rejection with endarteritis lost significance when adjusted for functional response after rejection treatment (hazard ratio [HR] for failure at 3 years decreased from 3.96 to 1.03 in patients with isolated endarteritis and from 3.39 to 1.13 in positive controls) ( Figure  3C ), likely reflecting the beneficial effect of functional recovery after rejection treatment, which was seen in approximately 80% of endarteritis groups. Table 2 lists the association of demographic, clinical, morphologic, and immunologic factors with kidney transplant failure in all 307 patients using complete univariate analysis and two multivariate Cox regression models. In all three groups with available antibody testing (n=117), positive DSA was not a significant prognostic indicator.
Independent Predictors of Kidney Transplant Failure
Multivariate analysis of 3-and 8-year survival included the study groups and the most important three covariates with lowest P values in univariate survival analysis (recipient age, transplant glomerulopathy, and functional response after treatment). None of the variables entered into multivariate analysis were collinear or highly correlated. To see the effect of response after rejection treatment, we built two models: with and without functional response after treatment. Multivariate models were limited to three variables to avoid model overfitting. In model 1, independent predictors of kidney transplant loss included recipient age (HR, 0.98; 95% CI, 0.96 to 1.00), transplant glomerulopathy (HR, 2.31; 95% CI, 1.02 to 5.24), type I acute T cell-mediated rejection with endarteritis (HR, 3.30; 95% CI, 1.08 to 10.14), and isolated endarteritis (HR, 3.51; 95% CI, 1.16 to 10.67). In model 2, which included the study groups, transplant glomerulopathy, and response to treatment, functional response after rejection treatment at 6 months was independently associated with a decreased risk compared with patients who were treated but had no response (HR, 0.28; 95% CI, 0.10 to 0.76). In model 2, isolated endarteritis and type I acute T cell-mediated rejection with endarteritis lost their poor prognostic significance. The beneficial effect of response after treatment was maintained at 8 years.
Multivariate analysis repeated with all variables with P,0.05 in univariate survival analysis for the entire followup period (median=3.2 years) provided the same conclusions as above (Supplemental Tables 1 and 2 ).
Factors Affecting Survival of Kidneys with Isolated Endarteritis
In the isolated endarteritis group, DSA, clinical versus protocol biopsy, v scores, interstitial inflammation score of 0 versus 1, and tubulitis score of 0 versus 1 were not significant risk factors at 3 and 8 years (P.0.05). The frequencies of transplant loss were 17% and 21% if isolated endarteritis was detected in protocol or clinical biopsies, respectively (P.0.05).
Transplant failure was seen in 25% of patients with untreated isolated endarteritis (3 of 12; at 1.1, 2.2, or 8.8 years after biopsy), 11% (6 of 55) of patients with treated isolated endarteritis with functional response, and 28% (7 of 25) of patients with treated isolated endarteritis without functional response. (Because few patients had follow-up data after 8 years, the survival analysis was done using data at 8 years.) At 8 years, kidney transplant survival was 83% in patients with untreated isolated endarteritis, 91% in patients with treated isolated endarteritis with functional response, 71% in patients with treated isolated endarteritis with no functional response, and 92% in negative controls (overall log rank P=0.02) ( Figure  4 ). Although patients with untreated isolated endarteritis had shorter transplant survival than patients with treated isolated endarteritis with functional response (83% versus 91%, respectively), this comparison did not reach statistical significance (pairwise log rank P=0.49). However, patients with treated isolated endarteritis with functional response showed better transplant survival compared with patients with treated isolated endarteritis without functional response (91% versus 71%, respectively; pairwise log rank P=0.03).
We also analyzed if isolated endarteritis was biased by antibody-mediated rejection (ABMR) by two approaches. First, we reclassified all patients (all C4d negative) according to the recently updated Banff 2013 criteria, which no longer include C4d positivity as a requirement for ABMR diagnosis. 17 Biopsies with glomerulitis+peritubular capillaritis$2 with glomerulitis.1 or transplant glomerulopathy.0 were classified as suspicious for ABMR, and biopsies with glomerulitis +peritubular capillaritis=0 or 1 and transplant glomerulopathy=0 were classified as no evidence for ABMR. We then excluded patients who met the aforementioned criteria for suspicious for ABMR (53 of 307) from survival analysis. At 8 years, kidney transplant survival was 81% in patients with isolated endarteritis with no evidence for ABMR, 86% in positive controls without evidence for ABMR, and 93% in negative controls (log rank P=0.02) ( Figure 5 ). Second, we repeated survival analysis of study groups in patients who were DSA-negative. Of 117 patients tested for DSA, 22 patients had positive DSA, and 95 patients did not have DSA. Within patients who were negative for DSA, kidney transplant survival at 8 years was 77.6% in patients with isolated endarteritis, 88.9% in positive controls, and 96% in negative controls (P=0.09) (Figure 6 ). Taking both analyses together, these data suggest that negative prognostic effect of isolated endarteritis is likely not biased by ABMR.
DISCUSSION
In this multicenter, collaborative, diagnostic, controlled study of 307 patients, isolated endarteritis was detected in 103 patients and associated with an adverse effect on long-term kidney transplant outcomes. The risk for kidney transplant failure was 3.51-fold higher in patients with isolated endarteritis compared with negative controls after adjusting for several clinical covariates. Conversely, functional improvement after the use of corticosteroid-based treatment was independently associated with reduced risk of kidney transplant failure at 3 and 8 years. Response rate after mostly anti-T cell-mediated rejection treatment was 80% in patients with isolated endarteritis. Therefore, decline in serum creatinine after corticosteroid-based treatment with or without T cell depletion medications seems beneficial in improving short-term function and long-term survival of kidney transplants with isolated endarteritis, possibly as a result of the treatment. Our data strongly suggest that isolated endarteritis behaves as true acute rejection and should be treated accordingly.
This study provides the first multicenter, evidence-based insights into isolated endarteritis of kidney transplants by comparing its clinical behavior and outcomes with two types of controls: type I acute T cell-mediated rejection with endarteritis and no diagnostic rejection. Patients with isolated endarteritis clinically behaved similarly to positive control patients, in whom inflammatory infiltration involved arteries, tubules, and interstitium of the kidney. Both rejection types often manifested with increased serum creatinine within the first 2 months after transplantation. Interestingly, patients with isolated endarteritis had received T cell depletion induction therapies more frequently than positive control patients, suggesting that isolated endarteritis in some patients represents a therapeutically altered form of rejection with a paucity of infiltrating mononuclear leukocytes in the tubulointerstitial compartment. Survival of kidney transplants with isolated endarteritis or type I acute T cell-mediated rejection with endarteritis was also comparable with increased incidence of transplant failures. Less than one fifth of isolated endarteritis was detected in protocol biopsies from well functioning transplants or associated with delayed graft function. The infrequent association between delayed graft function and isolated endarteritis might imply a relationship between increased exposure to donor antigens because of ischemic injury and rejection responses. Endarteritis is not recognized in native kidneys with ischemic injury; thus, it is unlikely that isolated endarteritis is simply an injury response per se.
Our data suggest that isolated endarteritis in a nonhighly sensitized population with C4d-negative biopsies commonly represents acute T cell-mediated rejection and may respond to anti-T cell therapy. Thus, our data support the Banff criteria for type II T cell-mediated rejection, which do not require interstitial inflammation or tubulitis to diagnose rejection. However, C4d negativity alone cannot exclude ABMR, which was recommended by the recently updated Banff 2013 criteria. 17 Despite exclusion of C4d-positive biopsies and ABO-incompatible/positive crossmatch kidneys, 18.3% (11 of 60) of patients with isolated endarteritis and available HLA antibody testing had DSA, and patients with isolated endarteritis had higher Response to rejection therapy was entered only in patients who received antirejection treatment, and it was defined as an improvement in renal function by a positive D creatinine value (difference between the serum creatinine value at biopsy and the serum creatinine value at 1 or 6 months after biopsy). frequencies of histologic lesions associated with ABMR (transplant glomerulopathy, arteriosclerosis, and glomerulitis) than control groups. However, DSA was not a significant risk factor for graft failure in isolated endarteritis or all three groups. This finding aligns with several large studies, which reported that not all DSAs are risk factors and that the majority of patients with DSA maintains long-term outcomes similar to patients who are not sensitized. [18] [19] [20] [21] In patients who are highly sensitized or have C4d-positive biopsies, however, frequency and effect of DSA-associated isolated endarteritis may be higher. The higher frequency of patients who were tested for DSA and treated with antiantibody strategies in the isolated endarteritis group compared with controls (despite similar rates of DSA positivity in the three groups) suggests that some clinicians viewed isolated endarteritis as antibody-mediated, at least in part. Indeed, two recent small series, in which 5 of 13 and 5 of 6 patients with isolated endarteritis had DSA, seem to support this notion. 12, 13 Furthermore, Lefaucheur et al. 22 found that 45% of patients with DSA and endarteritis did not recover with anti-T cell treatment and that most patients lost their transplanted kidneys. In the study by Lefaucheur et al., 22 82% of endarteritis with DSA was with v1 or v2 lesions, 44% of patients were C4d-positive, and most patients had microvascular inflammation, interstitial inflammation, and tubulitis, consistent with mixed acute rejection. Therefore, in patients with isolated endarteritis, DSA, and microvascular inflammation, adding anti-B cell/antibody-depleting strategies to corticosteroids may prolong graft survival, although this still needs to be examined. Isolated endarteritis became increasingly recognized after a microarray study reported minimal inflammatory gene expression signatures of negligible T cell activation, IFN-g, and chemokines in association with isolated endarteritis in the same biopsy. 9 This finding was later validated in independent patient cohorts and microarray-classifier diagnosed biopsies with isolated endarteritis as negative for T cell-mediated rejection. 10, 11 We interpret these molecular findings with caution. The classifiers were trained in index rejection biopsies with high inflammation (spectrum bias). Thus, establishment of gene signature classifiers to diagnose acute rejection would likely require use of a wide range of rejection states and not just extreme cases. Another potential explanation is that molecular tests gave falsenegative results in biopsies with isolated endarteritis because of sampling error, because negative molecular signatures were detected in one core and isolated endarteritis was microscopically detected in another core of the same biopsy.
We questioned why kidneys with isolated endarteritis and type I acute T cell-mediated rejection with endarteritis were at increased risk for failure, especially if T cell-mediated rejection is a treatable disease and has no poor prognostic significance according to recent studies. [22] [23] [24] The answer is that not all patients with endarteritis improve renal function after corticosteroids or T cell depletion therapies. Approximately 20% of patients in both groups of endarteritis did not show functional improvement after therapy, and 15%-17% of patients progressed to kidney transplant failure. Conversely, patients responding to therapy had less kidney transplant loss (5%). This finding was confirmed in multivariate survival analysis: adjustment for response to treatment significantly decreased the risk for transplant loss. Our results seem consistent with a recent report of 11 patients with isolated endarteritis who had poor long-term outcomes. 14 It is noteworthy to differentiate our results from the belatacept phase III trial, which showed higher rates of early endarteritis (18% versus 4%) and slightly less DSA (4% versus 7%) but superior renal function and comparable graft survival through 5 years in patients treated with belatacept versus cyclosporin, respectively. [24] [25] [26] Another study indicated that patients treated with belatacept had more T-regulatory cells in biopsies during rejection compared with patients treated with calcineurin inhibitor, 27 suggesting that belatacept may ease recovery from acute rejection by selective immune regulation. In contrast, most patients in our cohort were on calcineurin inhibitors, and endarteritis unresponsive to anti-T cell therapy was a poor prognostic indicator.
In conclusion, this study provides the first evidence-based clinical knowledge on isolated endarteritis in a large population. This is important, because there are currently no guidelines for diagnostic interpretation and treatment of isolated endarteritis. Our data indicate that isolated endarteritis should be diagnosed and treated as acute rejection to prevent longterm kidney transplant failure.
CONCISE METHODS
Patients
At seven American and Canadian centers, we retrospectively enrolled patients who underwent kidney transplantation and developed biopsyproven isolated endarteritis, type I acute T cell-mediated rejection with endarteritis (type I plus type II or III: tubulointerstitial rejection and endarteritis), or no diagnostic rejection between January of 1999 and December of 2011. Only one biopsy per patient was included (if there were multiple biopsies, the earliest biopsy fulfilling eligibility criteria was selected).
Eligibility criteria differed between the study groups. In group 1, patients were eligible if they had isolated endarteritis defined by Banff lesion scores 16 in biopsies as an arteritis score of at least 1 with a tubulitis score 0 or 1 and an interstitial inflammation score 0 or 1. In group 2 (positive controls), patients were eligible if they had type I acute T cell-mediated rejection with endarteritis with an arteritis score of at least 1 and both tubulitis and interstitial inflammation scores of 2 or 3. In group 3 (negative controls), patients were eligible if they had no diagnostic rejection defined as an arteritis score of 0 and both tubulitis and interstitial inflammation scores of 0 or 1.
Key exclusion criteria for all groups were diffuse or focal peritubular capillary complement C4d deposition detected by immunofluorescence or immunohistochemistry, blood group ABO incompatibility, or crossmatch positivity between donor and recipient. Biopsies with GN or thrombotic microangiopathy were excluded. Biopsies processed at each site within 2 months of the submission date of biopsies with isolated endarteritis meeting the above histopathologic criteria were selected as controls. To exclude bias in selection of controls, no clinical parameters beyond biopsy pathology features were matched. The centers included in this study collected data in compliance with local ethical and consent guidelines under approval by their Institutional Review Boards and provided only deidentified data for this study.
Expert Pathology Committee Review of Biopsy Specimens
Biopsies were reviewed, and their morphologic features were scored using international Banff criteria 15, 16 by a committee of expert transplant pathologists (B.S., S.M.B., L.D.C., P.R., and M.H.) who were blinded to the patients' clinical courses. All biopsies were adequate according to Banff criteria 16 and included at least two cores with two or more arteries. Biopsies that were confirmed by full consensus among committee members to meet the histopathologic eligibility criteria were enrolled.
Study Design
Renal function was assessed at 1 and 6 months after biopsy, and kidney transplant survival was determined 1, 3, and 8 years postbiopsy. In addition, anonymized donor and recipient clinical data at transplantation, maintenance immunosuppressive regimens, treatment of acute rejection at time of biopsy, and serum HLA antibody test results in the peribiopsy period were captured from each site for analysis. Antibody specificities were determined by either Luminex single antigen beads or FlowPRA single antigen I and II beads (One Lambda, Canoga Park, CA) after a positive HLA antibody screening test using FlowPRA beads or Quickscreen ELISA.
End Points
We had two primary end points: kidney functional response after rejection treatment, which was indicated by an improvement in renal function by a positive D creatinine value (difference between the serum creatinine value at biopsy and the serum creatinine value at 1 or 6 months after biopsy), and kidney transplant failure, which was defined as return to dialysis and/or retransplantation. Renal functional course after rejection treatment was studied in patients with endarteritis who received treatment compared with negative controls with no treatment.
Statistical Analyses
Means (6SDs), medians and ranges, and 95% CIs were determined for all continuous variables. All transplants that were functioning at 1, 3, or 8 years were given a censor time of 1, 3, or 8 years and assigned a transplant status of working, regardless of any failures in the periods after 1, 3, or 8 years, respectively. Survival analyses were performed after biopsies with the Kaplan-Meier method using log rank test and univariate and multivariate models with Cox regression using the backward stepwise (likelihood ratio) method. The assumption of proportional hazards over time was verified using the log-log graphic method and met by all covariates. Potential linearity of covariates was investigated by collinearity diagnostics before multivariate survival analysis. Data analyses were performed using SPSS 22 statistical software (IBM, Armonk, NY).
